Kornimate/medical-research-clean huggingface dataset:
expressing personal recollections in english or spanish to alleviate traumatic emotions (exprésate)

Conditions: Post Traumatic Stress Disorder

Summary: the purpose of this study is to test if expressive writing about traumatic events has positive changes in women living with post-traumatic stress.


Eligibility criteria:
inclusion criteria: 1. age ≥ 21 years 2. elevated ptsd symptoms as assessed by the post-traumatic stress disorder checklist scale-version dsm 5 (pcl-5) using a cut-off of 34 or above 3. on a stable anti-retroviral therapy regimen for \> 6 months as assessed with the adult aids clinical trial group structured interview 4. spanish-english bilingual as measured by the brief acculturation scale for hispanics (cut-off of 3), spanish speaker or english speaker 5. participant is willing and able to sign informed consent form (icf) 6. self-report as latina 7. hiv positive serostatus as determined by medical record within the last 12 months 8. born female. exclusion criteria: 1. left-handedness or ambidextrous 2. inability to tolerate the scanning procedures 3. metal in body or prior history working with metal fragments 4. any other contraindications for mri examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body) 5. currently pregnant or could be pregnant 6. heavy alcohol intake (\> 3 drinks) within 12 hours prior to participation in functional magnetic resonance imaging (fmri) 7. evidence from health history of neurological or systemic disorder which can cause cognitive impairment 8. self-reported current diagnosis of psychiatric disorder or psychoactive substance abuse or dependence 9. recent history (within two years) of myocardial infarction 10. severe cardiovascular disease, or currently active cardiovascular disease (e.g., angina, cardiomyopathy) 11. uncontrolled hypertension or hypotension 12. history of closed trauma with loss of consciousness 13. space occupying lesions (e.g., mass lesions, tumors) 14. central nervous system (cns) infection 15. cns vasculitis 16. cns demyelinating disease (e.g., multiple sclerosis) 17. congenital cns abnormality (e.g., cerebral palsy) 18. seizure disorders 19. history of cerebrovascular disease (e.g., stroke, tia's)
effect of cognitive behavioral therapy in patients with chronic nonspecific low back pain

Conditions: Low Back Pain, Mechanical

Summary: the purpose of the study is to determine the effectiveness of cognitive-behavioral therapy on functional outcomes, pain, and pain-related anxiety in patients with chronic nonspecific low back pain

back pain has considerable negative effects on the quality of life of affected individuals. individuals with new-onset back pain have an increased risk of lower quality of life scores, and the negative effect on quality of life increases with persistent pain. patients with chronic back pain report a quality of life that is lower than individuals without pain and that is comparable to those of individuals with life-threatening diagnoses. in addition, back pain is associated with worry and fears, particularly about the (sense of) self and socialrelationships and especially when pain persists longer than expected.

Eligibility criteria:
inclusion criteria: 1. thirty patients with non-specific chronic low back pain from both sexes will be included. 2. subjects with normal body mass index (18 to 25). 3. the age of patients range from 20 to 35 years. 4. duration of pain more than 3 months up to 2 years. 5. normal cognition score 26 or above according to moca scale.7. highly educated at least high school. exclusion criteria: the patients will be excluded if they have any of the followings: 1. lumbar canal stenosis. 2. lumbar discogenic lesions. 3. any inflammatory arthritis, tumors, infection involving the lumbar spine. 4. patients with decreased range of motion secondary to congenital anomalies, muscular contracture or bony block. 5. previous lumbar surgery or trauma. 6. subjects with a history of any neurologic disease. 7. cauda equina syndrome. 8. patients suffering from psychological, cognitive or emotional disturbance. 9. patients who had previously participated in cognitive behavioral therapy. 10. deafness and blindness.
dexmedetomidine prevents postoperative delirium after deep brain stimulation in patients with parkinson's disease

Conditions: Dexmedetomidine; Postoperative Delirium; Deep Brain Stimulation

Summary: postoperative delirium (pod) is a common complication, and the incidence of pod after deep brain stimulation(dbs) implementation ranges from 10% to 40%. previous studies suggested that aging and existing non-motor symptom were independent risk factors for pod after supratentorial tumor resections. therefore, patients undergoing dbs are high-risk populations for pod. a lot of trials show that dexmedetomidine might help to reduce the incidence of delirium in patients undergoing non-cardiac surgery. however, the impact of dexmedetomidine on pod for patients undergoing dbs was seldom reported. the purpose of this study was to investigate the effect of dexmedetomidine on pod in patients with parkinson' disease undergoing dbs.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease * exist non-motor symptoms * undergoing selective dbs. * age ≥60 years. * obtain written informed consent. exclusion criteria: * preoperative severe cognitive impairment (montreal cognitive assessment, moca\< 18) * history of psychoactive * allergic or intolerant to dexmedetomidine * severe bradycardia (heart rate lower than 40 beats/min) or sick sinus syndrome, second-degree or third-degree atrioventricular block * severe hepatic dysfunction (child-pugh class c) * severe renal dysfunction requiring renal replacement therapy before the surgery * medical records documented inability to communicate in the preoperative period due to language barrier or other situations.
telemark polyp study, a trial on colonoscopy screening

Conditions: Colorectal Cancer

Summary: colonoscopy screening to reduce mortality and incidence of colorectal cancer (crc) has been implemented in many western countries. the estimated effect is based on case-control and observational studies. there are no randomized trials quantifying the effect of colonoscopy screening on crc incidence and mortality. the present study investigates the effect of a population-based once-only colonoscopy screening with polypectomy on the incidence of crc in an average risk population. in 1983, 900 individuals 55 to 64 years of age were randomly drawn from the population registry of telemark county, norway. 400 of these were invited to a flexible sigmoidoscopy screening examination, and 400 individuals were not offered any screening. in 1996, the remainder, both cohorts from 1983 were invited to a colonoscopy screening examination. a new age and sex matched control group, not being offered screening, was randomly drawn from the same registry. both groups are to be followed with regard to crc incidence, crc mortality and all-cause mortality through national norwegian registries.

this as a randomized study of once-only colonoscopy screening (n=685) vs/no screening(care as usual)(n=684). men and women at 63-72 years of age are recruited from the population registry. the intervention group is invited for screening after a bowel cleansing regimen at home. follow-up is restricted to trace events (colorectal cancer incidence and deaths) through national registries.

Eligibility criteria:
inclusion criteria: * age 55 to 64 years old * both male and female exclusion criteria: - colorectal cancer diagnosed before study entry
measure of vaccine effectiveness to prevent hospitalizations for viral respiratory infections in adults

Conditions: Severe Acute Respiratory Infection (SARI); Influenza; COVID-19

Summary: this study is a prospective, multicentric, observational test negative design study on adults hospitalized for severe acute respiratory infection (sari), regardless of their vaccination status.

participation to the study will be systematically proposed to all patients hospitalized fitting inclusion criteria. patient's screening will be done in emergency department or hospital department with direct admission. medical investigators explain the objectives of the studies, procedure and propose the patient to participate in the study. socio-demographic data, clinical and virological data will be collected in an electronic clinical research form. a follow-up at 1 and 3 months after hospitalization discharge will be scheduled to evaluate health status. the remainder of respiratory samples that have been performed for care will be used for further testing depending on epidemiological situation and will be stored at -80°c.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * admitted in a hospital for at least 24 h * presents sari criteria within onset within the last 14 days before sampling and less than 48 h after hospitalisations: at least one of the following signs (without treatment): fever or feverishness, malaise, headache, myalgia or sign of fatigue (loss of weight or anorexia or confusion or dizziness) associated with at least one respiratory symptom or sign (cough, sore throat or shortness of breath; or tachypnoea or signs of low oxygen saturation) * completed non-opposition form * respiratory samples within 14 days after symptoms onset, in the context of care exclusion criteria: * contraindication of vaccination

Keywords: severe acute respiratory infection (sari) vaccine effectiveness influenza covid-19
a study of idh305 in patients with advanced malignancies that harbor idh1r132 mutations

Conditions: Advanced Malignancies That Harbor IDHR132 Mutations

Summary: a phase i study of idh305 in patients with advanced malignancies that harbor idh1r132 mutations.


Eligibility criteria:
inclusion criteria: * documented idh1r132-mutant tumors * ecog performance status ≤ 2 exclusion criteria: * patients who have received prior treatment with a mutant-specific idh1 inhibitor (with the exception of glioma patients) * medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease. * acute promyelocytic leukemia * women who are pregnant or lactating other protocol-defined inclusion/exclusion may apply

Keywords: idhr132 mutations idh305 idh idh1 aml acute myeloid leukemia leukemia myeloid acute mds myelodysplastic syndrome glioma oligodendroglioma astrocytoma glioblastoma cholangiocarcinoma solid tumors
the effect of glimepiride compared with sitagliptin as an add-on therapy to metformin in severe insulin deficiency diabetes

Conditions: Diabetes Mellitus, Type 2; Severe Insulin Deficient Diabetes

Summary: the purpose of the trial is to verify the effectiveness and safety of glimepiride compared with sitagliptin as an add-on therapy to metformin in severe insulin deficiency diabetes.

this clinical trial is a multi-centre, prospective, intervention, randomized-controlled clinical trial, and uses a superiority test to determine whether the experimental group is superior to the control group in terms of main efficacy endpoints.

Eligibility criteria:
inclusion criteria: * according to the world health organization (the who) 1999 criteria for the diagnosis of type 2 diabetes; the subtype was allocated to severe insulin deficiency diabetes (sidd) at diagnosis using data-driven diabetes clusters app. * men and women aged ≥ 18 years and ≤ 75 years; * diagnosed as severe insulin deficiency diabetes by the cluster classifier of peking university people's hospital at the initial stage of the disease course; * metformin monotherapy with dosage ≥1500 mg/day for at least 8 weeks; * diabetes duration less than 5 years; * the hba1c value of the central laboratory before randomization: 7.0% ≤ hba1c \<10.5% * estimated estimated glomerular filtration rate (egfr)\>=60 ml/min1.73m2, alanine aminotransferase(alt)\<120u/l ; * if other drugs are used during the course of the disease, these drugs should be withdrawn for more than 8 weeks; * without acute diabetic complications at present. exclusion criteria: * type 1 diabetes or other special types of diabetes mellitus; glutamic acid decarboxylase antibody (gada) positive, the subtype was allocated to other subtypes at diagnosis using data-driven diabetes clusters app. * pregnancy or have a pregnancy plan within a year; * lactation or have a lactation plan within a year; * renal insufficiency, egfr\ = 120u/l; unstable coronary heart disease. * recurrent spontaneous diabetic ketosis or uncorrected acute diabetic complications; * participated in other clinical trials within 8 weeks before randomization; unable to complete the study follow-up for 6 months; have situations such as operation and need to change to insulin therapy in 6 months. * use concomitant medication such as glucocorticoids which can affect blood sugar. * the investigator judged that it is not suitable to participate in this clinical trial.
study of a new topical natural health product for the treatment of herpes labialis

Conditions: Herpes Labialis

Summary: the aim of this study is to determine the safety and efficacy of a topical natural health product in comparison to placebo for the treatment of herpes labialis.


Eligibility criteria:
inclusion criteria: * female and male, in good health, 18 years of age or older, * with history of recurrent herpes labialis with at least twice a year during the past twenty-four months, * agreeing not to take another treatment against cold sore, nor anti-inflammatory, antibiotics and steroids, * cooperating in the study, able to be monitored at each visit, aware of the demands and duration of the controls, thus allowing perfect adherence to the established protocol, * must be willing and able to participate and to provide written informed consent, * female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study. exclusion criteria: * volunteers who refuse to introduce the product to be tested in its routine, * with a history of hypersensitivity to the type of product to be tested (e.g., products that contain essential oil), * who have a history of eczema, topical dermatitis, psoriasis or significant skin anomalies on the areas to be tested, * who suffer from a serious illness or health problem or a critical or progressive disease, * who have taken prescription or over the counter medication that could affect skin characteristics or could bias the study (i.e. antibiotics, antihistamines, anti-inflammatories...) within 7 days prior to study beginning, * who have recently acquired or who currently have significant skin pigmentation, who frequent tanning salons or foresee exposure to the sun during the study, * who abuse alcohol, drugs and/or tobacco, * female subjects who are pregnant, breastfeeding or expecting to become pregnant during the study.
clinical evaluation of toric intraocular lens

Conditions: Cataract; Astigmatism

Summary: evaluate efficacy and safety of the toric iol implanted into aphakic eye with corneal astigmatism after cataract surgery.

effectiveness * primary endpoint is visual acuity with pre-determined spherical correction. * secondary endpoint is ucva with spherical correction, bscva, refractive cylinder correction, spherical equivalent, iol rotation safety * number and percentage of adverse event

Eligibility criteria:
inclusion criteria: * patients with age of 40 years or older * patients with age-related cataract in one eye or both eyes. * patients willing to participate in the required postoperative study. * patient who can understand and sign the consent document. * an eye whose pupil diameter after mydriasis is 5 mm or greater. * an eye whose preoperative corneal cylindrical power is 1.0d or more. * an eye whose postoperative astigmatism is predicted to be less than 0.5 d. * an eye whose postoperative visual acuity with spherical addition is 0.8 d or more. exclusion criteria: * disorder of corneal endothelium * uncontrolled glaucoma * active uveitis * diabetic retinopathy * retinal detachment * congenital ocular anomalies * choroidal hemorrhage * shallow anterior chamber * microphthalmus * corneal dystrophy * optic atrophy * ocular hypertension * amblyopia * previous history of corneal transplantation * active iritis * corneal disorder * macular degeneration * retinal degeneration * clinically significant change in macula and/or retinal pigment epithelium * corneal irregular astigmatism * atopic disease * brittleness of zinn's zonule, fractured zonule and lens luxation (including subluxation) * pseudo-exfoliation syndrome * iris neovascularization * long axis length eye (axis length : 28mm or more) * severe dry eye, abnormality of the lens surface * concurrent participation in another drug and device clinical investigation * patient with mental deficiency or psychiatric disorder and/or who is not capable of expressing the consent of participating in the trial * patient who is judged inappropriate by investigators or sub-investigators
the effect of virtual reality-mediated rehabilitation in ischemic stroke patients

Conditions: Hemiplegia

Summary: the aim of the study was to investigate the effectiveness of virtual reality-mediated upper extremity rehabilitation added to the conventional rehabilitation program on upper extremity, quality of life, range of motion and spasticity in patients with stroke.

this prospective, randomized and controlled study will be conducted with patients diagnosed with stroke. among the patients who are admitted to outpatient or inpatient rehabilitation program in sbu kanuni sultan süleyman pmr clinic, 30 patients diagnosed with stroke who meet the inclusion criteria will be included in the study. patients diagnosed with stroke will be randomized into two groups using a computer program (virtual reality group, control group). participants in both groups will receive a conventional rehabilitation program. participants in the virtual reality group will receive virtual reality-mediated upper extremity rehabilitation for 3 weeks, 5 sessions per week, each session lasting 30 minutes (total 450 minutes). in the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the sensorehab® sensor that can detect hand movements through gloves. 3 different games will be intervened for 10 minutes each, totaling 30 minutes per day. participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist. after the intervention, patients will be evaluated in terms of upper extremity functions, quality of life, range of motion and spasticity. all evaluations will be repeated before, after and 3 months after the intervention. routine 3-month pmr outpatient clinic control is recommended for patients with stroke. therefore, no additional hospital visit is requested from the patients due to the study.

Eligibility criteria:
inclusion criteria: * 18 to 65 years of age, * history of ischemic stroke * accept to participate in the study, exclusion criteria: * presence of known central nervous system or peripheral nervous system disease other than stroke, presence of progressive neurologic deficit, * uncontrolled hypertension, diabetes, cardiovascular disease etc. * cognitive impairment causing difficulty in executing simple commands * epilepsy * botulinum toxin application to the upper extremity in the last 6 months * change in the medical treatment used for spasticity in the last 6 months * pregnancy.
a study collecting remote data in people with an overweight condition or obesity on a weight management program

Conditions: Overweight, Obesity

Summary: the purpose of this study is to collect health data related from participants living with an overweight condition in a decentralised clinical study set-up. all data will be collected remotely using an app downloaded on your personal smartphone and devices (watch and scale). participants will participate in this study for 24 weeks. the study does not include any study medicine.


Eligibility criteria:
inclusion criteria: 1. informed electronic consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. willingness to consent via the e-consent process before any study-related activities (study- related activities are any procedure related to recording of data according to the protocol 3. male or female, age above or equal to 18 years at the time of signing informed consent 4. body mass index (bmi) above or equal to 25 kg/m\^2 5. undergoing at least one of the following weight management program(s) as prescribed/ agreed upon by the treating physician: 1. diet regime aimed at losing weight and/or 2. exercise regime aimed at losing weight and/or 3. prescription of any approved anti-obesity medication (according to standard practice) 6. willingness to follow study procedures 7. willingness to, and capable of using the study devices and app 8. fluent in oral and written danish language 9. in possession of a compatible smartphone (minimum android 10 and ios14) throughout the study that has a reliable internet connection, regular connection to 4g/5g network, or wi-fi and that has the capability of downloading the study app and connecting with the smartwatch, the body composition scale and the data hub) exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. participation in any study investigating an overweight condition or obesity 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation 4. type 1 or type 2 diabetes 5. currently under treatment with any glp-1 ra with the indication of improving glycaemic control 6. currently using a pacemaker, an implantable cardioverter-defibrillator (icd) or cardiac resynchronisation therapy (crt) due to the electrical effects of the body composition scale 7. female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an effective contraceptive method during the study duration